Synopsis-
“The Food and Drug Administration (FDA) on Friday gave the nod to the first Non Hormonal Medication for the treatment of hot flashes, a medical condition in which the upper body part of women gets overheated and extreme sweating occurs.”
There are times when menopause can become a problem as menstrual periods become irregular and eventually stop. These are symptoms of hot flashes, the most common one of menopausal transitions.
The Food and Drug Administration (FDA) on Friday gave the nod to the firstNon Hormonal Medication for the treatment of hot flashes, a medical condition in which the upper body part of women gets overheated and extreme sweating occurs.
The non hormonal medication to be marketed as Veozah is the first to target a neuron in the brain that gets unbalanced as estrogen level falls. The drug is genuinely for women who are in their 50s during the menopausal phase estimated to last seven years as per Astellas Pharma.
What are the first signs of hot flashes- why do they matter?
Periodic body overheating is a common and one of a few early signs of hot flashes of menopause and according to Astellas Pharma, it affects at least 60 percent of women.
Dr Janet Maynard, an official with the F.D.A. Center for Drug Evaluation and Research, said, “Hot flashes as a result of menopause can be a serious physical burden on women and impact their quality of life.”
Hormonal imbalances like hot flashes can be prolonged and disturb basic functions in daily life.
What is the most common effective treatment for hot flashes?
Since hot flashes often occur in menopause for which women typically need treatment, the pharma company says.
In yearlong studies, the medicine was found to be useful and generally safe, with side effects including diarrhoea, stomach pain, and insomnia as per the F.D.A.
What’s Next: The drug price may be proscriptive
Astellas Pharma said that the medicine would cost $550 for a 30-day supply, not including rebates.
